N/A N=62

Processing Speed as an Objective Measure of Tinnitus

Tinnitus

Bottom Line

View on ClinicalTrials.gov: NCT01222507 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2012

Primary outcome: Primary: Brain Speed Test — -0.28 units on a scale

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Washington University School of Medicine
Primary completion: Oct 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Brain Speed Test	-0.28	—

Summary

The overall purpose of this research is to assess whether both the "60 second Brain Game" and the "Brain Speed Test" computer-based programs can be used as assessment tools for objectively defining the severity of the functional impact of tinnitus.

Eligibility Criteria

Inclusion Criteria

Participants must be between the ages of 18 and 80.
Participants must have subjective, unilateral or bilateral, non-pulsatile tinnitus of 6-months duration or longer.
Participants must be able to read, write and speak using the English language.
Participants must be able to provide informed consent.

Exclusion Criteria

Participants with tinnitus related to Workman's Compensation Claim or other litigation-related situations.
Participants with active diagnoses of any acute or chronic brain-related neurological conditions that alter normal brain anatomy or function including Parkinson's disease, Multiple Sclerosis, Alzheimer's Disease, cerebral infarcts, traumatic brain injury, history of brain tumor(s), epilepsy, or dementia.
Participants with tinnitus related to retrocochlear lesions, cochlear implants, or other known anatomic/structural lesions of the brain, skull-base, temporal bone or ear.
Participants unable to hear the highest volume of the computer-based objective assessments.
Any medications that may affect or alter cognition including but not limited to sedatives, hypnotics, narcotics, or opiates.
Any medical condition the PI determines would compromise the safety of the participant or complicate the interpretation of the study results.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01222507). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.